ESSA Pharma 2021 Bloom Burton Healthcare Conference

ESSA Pharma presented at the 2021 Bloom Burton & Co Healthcare Investor Conference, showcasing its development of first-in-class N-terminal domain inhibitors (Anitens) for prostate and hormone-driven cancers. The company highlighted EPI-7386 Phase 1 clinical development focused on resistant mCRPC and potential applications in CRPC, CSPC, and triple-negative androgen receptor-positive breast cancer.